A Phase 1/2 interventional study of CM310 and Placebo in Moderate-to-severe Atopic Dermatitis, sponsored by Keymed Biosciences Co.Ltd. Completed at 7 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-06-04.
Sponsored by Keymed Biosciences Co.Ltd · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing stapokibart in Dermatitis, Atopic — 2 open to participants now, 3 under way, 3 of them phase 3. stapokibart · Dermatitis, Atopic.
Among the 12 studies testing stapokibart in Dermatitis, Atopic, this one is the 10th largest by enrollment, is the only one that started in 2020, is one of 2 in phase 1/2, and was the 2nd registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 12 studies testing stapokibart in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Keymed Biosciences Co.Ltd · Sites in China
Ages 2–12
Keymed Biosciences Co.Ltd · Sites in China
Ages 2–11
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 5
First in 2020; this study’s year is marked. 1 started in 2020.
This study's enrollment of 39 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 170 across the 12 interventional studies. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 1 most frequent:
Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.
18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd: 4 open now, 5 under way, 3 of them phase 3. Of 10 finished, 0 (0%) have results posted.
Among the 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd, this one is the 16th largest by enrollment, is the only one that started in 2020, is one of 3 in phase 1/2, and was the 2nd registered.
Keymed Biosciences Co.Ltd’s Dermatitis, Atopic studies by the year they started, since 2020.
1 of the studies testing stapokibart in Dermatitis, Atopic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07106372Phase 3Keymed Biosciences Co.LtdA Study of Stapokibatrt in Children Subjects With Atopic Dermatitis | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing stapokibart in Dermatitis, Atopic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Keymed Biosciences Co.Ltd’s 18 in Dermatitis, Atopic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized, double blind, placebo-controlled multiple dose escalation study to evaluate the safety, tolerance, PK, PD, immunogenicity and preliminary efficacy of subcutaneously CM310 in moderate-severe AD subjects.
The study consists of 3 periods, a up-to-4-week Screening Period, a 4-week randomized Treatment Period and a 8-week Safety Follow-up Period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
75mg for 3 doses, every 2 weeks, SC
Drug: CM310
150mg for 3 doses, every 2 weeks, SC
Drug: CM310
300mg for 3 doses, every 2 weeks, SC
Drug: CM310
600mg for 1st dose, and then 300 mg for 2nd and 3rd doses, every 2 weeks, SC
Drug: CM310
placebo for 3 doses, every 2 weeks, SC
Drug: Placebo
IL-4Rα monoclonal antibody
Placebo
Safety parameters (e.g., Incidence of AE, abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing)
Incidence of AE, abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.
Time frame: Baseline to Week 12
Pharmacokinetics parameter: Peak concentration (Cmax)
Peak concentration (Cmax)
Time frame: Baseline to Week 12
Pharmacokinetics parameter: Area under the plasma concentration-time curve from 0 to ∞ (AUC0-∞)
Area under the plasma concentration-time curve from 0 to ∞ (AUC0-∞)
Time frame: Baseline to Week 12
Pharmacokinetics parameter: Area under the plasma concentration-time curve from 0 to t (AUC0-t)
Area under the plasma concentration-time curve from 0 to t (AUC0-t)
Time frame: Baseline to Week 12
Pharmacokinetics parameter: Clearance rate (CL/F)
Clearance rate (CL/F)
Time frame: Baseline to Week 12
Pharmacodynamics parameters: Serum Thymus and activation regulated chemokine (TARC)
Serum Thymus and activation regulated chemokine (TARC), total IgE level and blood eosinophil count (EOS)
Time frame: Baseline to Week 12
Pharmacodynamics parameters: Blood eosinophil count (EOS)
Blood eosinophil count (EOS)
Time frame: Baseline to Week 12
Pharmacodynamics parameters: Total IgE level
Total IgE level
Time frame: Baseline to Week 12
Immunogenicity: Proportion of subjects with anti-drug antibody (ADA)
Proportion of Participants with anti-drug antibody (ADA)
Time frame: Baseline to Week 12
Preliminary efficacy: Proportion of subjects with IGA 0 or 1
Proportion of subjects with Investigator's Global Assessment (IGA, on a 6-point scale, range from 0-5 point, higher scores mean a worse disease severity) 0 or 1
Time frame: Baseline to Week 12
Preliminary efficacy: Proportion of subjects with a reduction of IGA from baseline of ≥ 2 points
Proportion of subjects with a reduction of IGA from baseline of ≥ 2 points
Time frame: Baseline to Week 12
Preliminary efficacy: Proportion of subjects with IGA 0 or 1 and a reduction of IGA from baseline of ≥ 2 points
Proportion of subjects with IGA 0 or 1 and a reduction of IGA from baseline of ≥ 2 points
Time frame: Baseline to Week 12
Preliminary efficacy: Proportion of subjects with EASI-50
Proportion of subjects with The Eczema Area and Severity Index(EASI)-50 (≥50 percent improvement from baseline)
Time frame: Baseline to Week 12
Preliminary efficacy: Proportion of subjects with EASI-75
Proportion of subjects with EASI-75 (≥75 percent improvement from baseline)
Time frame: Baseline to Week 12
Preliminary efficacy: Proportion of subjects with improvement (reduction) of pruritus NRS from baseline
Proportion of subjects with improvement (reduction) of pruritus Numerical Rating Scale(NRS) from baseline; The range of NRS is from 0 (no itch)-10 (worst imaginable itch)
Time frame: Baseline to Week 12
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2020 to primary completion in Jan 2021, 6 months.
Of 25 industry-sponsored phase 1/2 interventional studies under Dermatitis, Atopic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's 6 months is below that.
Counting every sponsor, half of 29 studies reached it within 22 months; a quarter within 8 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Stapokibart